Skip to main content
. 2019 Mar 13;54(8):752–761. doi: 10.1007/s00535-019-01569-7

Fig. 1.

Fig. 1

Overall SVR12 comparing Japan and overseas rates by genotype. Efficacy of 8-week G/P treatment defined as SVR12 is reported for both Japan and overseas patients by genotype using an ITT analysis. The table lists the reason for non-response including virologic (breakthrough or relapse) and non-virologic failure (premature discontinuation or missing SVR12) for each group. Premature d/c, Premature discontinuation